Menu Back toSession 3: Industry Best Practices and FDA Feedback on Optimal Combination Product Submissions
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Combination Products Conference
Session 3: Industry Best Practices and FDA Feedback on Optimal Combination Product Submissions
Demetra Macheras, MBA
- Director, Regulatory Policy and Intelligence - Regulatory Affairs
- AbbVie, Inc., United States
Have you ever struggled with how and where to address certain information within your combination product submission? This session will provide an overview of pitfalls and lessons learned from both industry and FDA regarding where information is best located to provide a clearly structured and efficient combination product submission to FDA. Topics to be covered will include key FDA guidance and resources that support the location of key combination product information, real world experience from industry, and pitfalls and best practices in the structure and format of combination product submissions experienced by both CDER and CBER.
Learning Objective : At the conclusion of this session, participants should be able to:
- Define FDA guidances and resources that address FDA expectations for the location of key information in a combination product submission
- Explain industry knowledge and lessons learned on where to locate certain combination product-related information within a submission
- Understand FDA recommendations on where to locate key information in a combination product submission
Evolution of the NDA/BLA Content for a Combination Product
Susan Holmes, MSc
- GlaxoSmithKline, United States
Best Practices and Recommendation for Combination Product Submissions to CDER
Kristina Lauritsen, PhD
- Combination Products Regulatory Policy Advisor, OEP, CDER
- FDA, United States
Considerations for Submission of Device Information
Sarah Mollo, PhD, RAC, PhD, RAC
- Combination Product Policy Analyst, OPEQ, CDRH
- FDA, United States